centerforbiosimilars7 小时
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory ...
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
centerforbiosimilars14 小时
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
centerforbiosimilars2 天
Lisa Lasita, PharmD, MBA
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME ...
centerforbiosimilars2 天
Josh Canavan, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2 天
Dinakaran Balasubramanian
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2 天
Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
centerforbiosimilars3 天
Skylar Jeremias
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key ...
centerforbiosimilars3 天
Gary Fanjiang, MD, MBA, MS
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3 天
Derek Burns, PharmD, MBA, BCPS, BCSCP
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3 天
Peter Pitts
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3 天
Nancy J. Globus, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...